MET and neoplasm: In a large study of 1,387 lung cancer cases, the expression of PDL1 was reportedly high in 49% of MET mutated cases (compared to 29% of MET wild type), while tumor mutation burden was significantly lower in MET mutated cancers compared to wild-type tumors [36].